For the quarter ending 2025-09-30, ELVN had -$22,439K decrease in cash & cash equivalents over the period. -$54,621K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -74,027 | - |
| Depreciation | 217 | - |
| Stock-based compensation | 21,708 | - |
| Non-cash lease expense | 261 | - |
| Amortization of premiums and discounts on marketable securities, net | 282 | - |
| Change in fair value of contingent value right liability | 0 | - |
| Prepaid expenses, other current and long-term assets | 411 | - |
| Operating lease liabilities | -246 | - |
| Accounts payable | -11 | - |
| Accrued expenses and other liabilities | -1,672 | - |
| Net cash used in operating activities | -54,463 | - |
| Maturities of marketable securities | 185,209 | - |
| Purchases of marketable securities | 371,271 | - |
| Receipt of contingent value right milestone | 0 | - |
| Payment of contingent value right milestone, net of permitted deductions | 0 | - |
| Purchases of property and equipment | 158 | - |
| Net cash used in investing activities | -186,220 | - |
| Proceeds from exercise of stock options | 1,767 | - |
| Proceeds from issuance of common stock under the espp | 427 | - |
| Proceeds from issuance of common stock and pre-funded warrants in the public offering, net of issuance costs | 216,169 | - |
| Proceeds from issuance of common stock and pre-funded warrants in the private placement, net of issuance costs | 0 | - |
| Payment of deferred offering costs | 119 | - |
| Net cash provided by financing activities | 218,244 | - |
| Restricted cash | - | 0 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -22,439 | - |
| Cash and cash equivalents, at carrying value, total | - | 119,437 |
| Cash and cash equivalents at beginning of period | 124,171 | - |
| Cash and cash equivalents at end of period | 101,732 | 119,437 |
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)